Limitations, agreements, and source contact

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy · Source last updated 2023-09-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details

This submission /document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.

pi Sponsor Employee

false

restriction Type

OTHER

restrictive Agreement

true

point Of Contact

email

information.center@astrazeneca.com

organization

AstraZeneca AB

phone

1-877-240-9479

title

Global Clinical Leader

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice